Press Releases

2015.08.03 Corporate PDF (13KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2015.07.31 IR PDF (33KB)
Revision to “Results Briefing (Results for Q1 FY2015)”
2015.07.27 CSR PDF (72KB)
Daiichi Sankyo Announces New Social Contribution Initiative in Yunnan Province, China, to Support Health Improvement for Mothers and Children
2015.07.07 Corporate PDF (12KB)
Daiichi Sankyo Announces Details of Executive Share Options
2015.07.01 Local (JPN) PDF (103KB)
13th Takamine Memorial Daiichi Sankyo Prize Winner Announced
2015.07.01 Corporate PDF (96KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2015.06.30 Corporate PDF (42KB)
Announcement Regarding Issuing of Shares and Total Underwriting of Shares by Kitasato Daiichi Sankyo Vaccine
2015.06.26 Local (JPN) PDF (68KB)
Application for Marketing Authorization for Lacosamide (Generic Name) in Japan for the Treatment of Epilepsy
2015.06.25 Products PDF (378KB)
Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
2015.06.25 Local (JPN) PDF (148KB)
Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 8th Annual Clinical Pharmacology Research Award
2015.06.23 Local (JPN) PDF (73KB)
Daiichi Sankyo to Collaborate with Maruishi Pharmaceutical on Commercialization of General Anaesthesia Analgesic, Remifentanil Injection Generic
2015.06.22 Corporate PDF (164KB)
Daiichi Sankyo to Issue Share Options as Remuneration
2015.06.19 R&D PDF (179KB)
Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
2015.06.18 Local (JPN) PDF (328KB)
Daiichi Sankyo Launches New Generic Drugs Through its Daiichi Sankyo Espha Subsidiary
2015.06.01 Local (JPN) PDF (97KB)
Daiichi Sankyo Announces Lifting of Prescription Period Limitation for Antiplatelet Agent Efient® 3.75mg/5mg Tablets in Japan
2015.06.01 Corporate PDF (96KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2015.05.22 Corporate PDF (58KB)
Daiichi Sankyo Announces Changes to Audit and Supervisory Board at Domestic Subsidiaries
2015.05.19 Local (JPN) PDF (16KB)
Daiichi Sankyo Announces Cooperative Sales Agreement for the Influenza HA Vaccine “Kaketsuken”
2015.05.14 Corporate PDF (179KB)
Daiichi Sankyo Announces Changes to Representative Directors, Members of the Board, and Members of the Audit and Supervisory Board
2015.05.14 Corporate PDF (59KB)
Daiichi Sankyo Announces Dividend Forecasts for Fiscal 2015 (Commemorative Dividend to Mark 10th Anniversary)
2015.05.14 Corporate PDF (58KB)
Daiichi Sankyo Announces Determination of Matters Relating to Acquisition of Treasury Shares
2015.05.14 Corporate PDF (91KB)
Differences Between Consolidated Results for Fiscal 2014 and Fiscal 2013
2015.04.28 Corporate PDF (120KB)
Daiichi Sankyo Revises Fiscal 2014 Consolidated Forecasts
2015.04.28 Corporate PDF (58KB)
Daiichi Sankyo Announces Write-off Loss on Trade Rights Related to Consolidated Subsidiary Plexxikon Inc.’s Anticancer Agent Zelboraf
2015.04.28 Corporate PDF (58KB)
Daiichi Sankyo Announces Booking Extraordinary Losses in its Non-consolidated Financial Results for Fiscal 2015 (Japanese GAAP)
2015.04.27 Products PDF (111KB)
Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
2015.04.21 Corporate PDF (15KB)
Daiichi Sankyo Completes Sale of Sun Pharma Shares
2015.04.20 Corporate PDF (19KB)
Daiichi Sankyo to Sell Shares of Sun Pharma
2015.04.15 Products PDF (113KB)
Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
2015.04.10 Local (JPN) PDF (121KB)
Daiichi Sankyo and Terumo Announce Application in Japan for Manufacturing and Sales Approval of Intradermal Seasonal Influenza Vaccine
2015.03.26 Corporate PDF (64KB)
Announcement Regarding Closure of Merger Between Daiichi Sankyo Subsidiary Ranbaxy and Sun Pharma (Additional Disclosure)
2015.03.25 Corporate PDF (64KB)
Announcement Regarding Closure of Merger Between Daiichi Sankyo Subsidiary Ranbaxy and Sun Pharma
2015.03.20 Local (JPN) PDF (63KB)
Daiichi Sankyo Launches Methemoglobinemia Treatment Methylene Blue Injection 50mg
2015.03.20 Corporate PDF (48KB)
Daiichi Sankyo Signs Agreement with AstraZeneca to Co-commercialize MOVANTIK™ in the US
2015.03.17 Local (JPN) PDF (51KB)
Daiichi Sankyo to Facilitate New Drug Discovery in 2015 through Collaborative Research and Grants
2015.02.24 Corporate PDF (31KB)
Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2015
2015.02.24 Corporate PDF (76KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2015.02.09 Products PDF (163KB)
SAVAYSA™ (edoxaban) Now Available in U.S. Pharmacies
2015.02.04 R&D PDF (89KB)
Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
2015.01.29 IR PDF (455KB)
Ranbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec’14 Sales Rs.81,778 Mn
2015.01.13 Corporate PDF (42KB)
Daiichi Sankyo, Inc. Announces Civil Settlement
2015.01.09 Products PDF (139KB)
U.S. FDA Approves Daiichi Sankyo’s Once-Daily SAVAYSA™ (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism
2015.01.05 Local (JPN) PDF (18KB)
Daiichi Sankyo Receives Approval in Japan for the Manufacture and Marketing of Methemoglobinemia Treatment Methylene Blue Injection 50 mg

In order to view the PDF files, you need to have Adobe Reader 5.0 or later version installed.